HIGHLIGHTS
- who: Rodanthi Vamvoukaki et al. from the Endocrinology and Diabetes Clinic, University Hospital of Heraklion, School of Medicine, University of Crete have published the research work: Pituitary Tumorigenesisu2014Implications for Management, in the Journal: Medicina 2023, 59, 812. of /2023/
- what: This study provides evidence that BRAF/MEK inhibitors might be a good option for the treatment of previously untreated PCP. Study, dopastatins were developed (BIM-23A387 and BIM-23A760), showing a reduced GH and PRL secretion in the primary cultures of somatotropinomas, especially in the tumors with a partial response to octreotide and lanreotide .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.